SmallCapReview - Stocks to Watch - SCLW, ATLS,CTIC

SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com/.

Socialwise (OTCBB: SCLW) $0.66. Announced yesterday that professional skateboarder and 2010 Nickelodeon Kids' Choice Awards Favorite Male Athlete Ryan Sheckler has signed a deal with the Company to promote its online BillMyParents payment solution. Sheckler will be part of a major marketing initiative the Company plans to launch in late spring which will include a multitude of top action sports athletes and retailers.

The star of MTV's hit reality show " Life of Ryan," Ryan Sheckler is the skateboarding child prodigy who exploded onto the professional scene in 2003, turning pro at the tender age of 13. That year alone saw him astound the world with gold medals in street at the X Games and the Gravity Games. He also took first place overall in the Vans Triple Crown street competition. A native of San Clemente, CA, Ryan has also created The Sheckler Foundation to make a difference in the lives of children, families and communities in need, as well as injured action sports athletes. The first athlete to ever win the Dew Action Sports Tour championship 3 years in a row, Ryan continues to be an innovative and powerhouse skateboarder and international celebrity, with 1.5 million followers on Twitter alone.

"I love what BillMyParents is doing for teens and tweens," says Sheckler. "Teens need their independence, and using the BillMyParents payment systems means they can pick exactly what they want - it's very easy, and is also secure for parents. I have a close relationship with my mom, and I believe it's important for kids and their parents to talk about building good habits."

What They Do: Socialwise, Inc. seeks to capitalize on the explosive growth of online commerce. They develop platforms that integrate into traditional eCommerce products and services. Their flagship product offering is an online payment solution for young people, BillMyParents. BillMyParents provides payment solutions targeted to young people between the ages of 8 and 21. Solutions include both Supervised Shopping and MasterCard prepaid card with options ranging from giving parents complete control over purchases to simply monitoring purchase transactions. Their solutions facilitate communication between parents and young people and help teach financial responsibility.

Atlas Energy (Nasdaq: $31.81) Today announced its entry into a joint venture transaction with a wholly owned affiliate of Reliance Industries Limited, the largest private sector company in India and a global energy leader, pursuant to which Atlas will transfer an interest in its Marcellus Shale position equal to 120,000 net acres in a transaction valued at $1.7 billion. Reliance will pay approximately $340 million in cash upon closing and an additional $1.36 billion in the form of a drilling carry. Atlas will serve as the development operator for the joint venture. Reliance will have the option to operate in certain project areas in the coming years outside of Atlas’ core operating areas of Fayette, Greene, Washington, and Westmoreland Counties in southwestern Pennsylvania.

Pursuant to the agreement, Reliance will acquire a 40% undivided interest in approximately 300,000 net acres (120,000 net to Reliance) of undeveloped leasehold held by Atlas, and Atlas will retain a 60% undivided interest in the acreage. In addition to funding its own 40% of drilling obligations, Reliance has agreed to fund 75% of Atlas’ respective portion of drilling and completion costs until the $1.36 billion drilling carry is fully utilized. Atlas has 5-1/2 years to utilize the drilling carry, subject to a two-year extension under certain conditions. Atlas and Reliance have agreed upon a five-year development plan that calls for the drilling of 45 horizontal Marcellus Shale wells for the joint venture during the remainder of 2010, increasing to 108 wells in 2011, 178 wells in 2012, and 300 wells in 2013 and 2014.

What They Do: Atlas Energy is one of the largest independent natural gas producers in the Appalachia and Michigan Basins and a leading producer in the Marcellus Shale in Pennsylvania.

Cell Therapeutics (Nasdaq: CTIC) $0.64. Today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration (the "FDA") regarding its New Drug Application ("NDA") for Pixuvri (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").  The FDA cited as its primary reason for the action its concerns previously raised at the Oncologic Drugs Advisory Committee ("ODAC") meeting on March 22, 2010 and recommended the Company conduct an additional trial to demonstrate the safety and effectiveness of its product.   Based on the FDA's ODAC presentation, which provided the Committee and the Company with alternative options to consider to make investigational drugs available to patients if drugs need to be studied further prior to approval, the Company has decided to pursue expanded access program for pixantrone while it conducts an additional study in aggressive NHL.

"On the basis of discussing the PIX 301 clinical trial results with directors of more than 50 of the largest academic and community based lymphoma treatment centers across the U.S., we expect enrollment in a follow-up combination therapy study in a similar population could be rapid and occur predominantly within the U.S.," noted Jack W. Singer, M.D., Chief Medical Officer of the Company. "We have had preliminary discussions on the subsequent trial design with a leading statistician, and potential lead investigators who believe the study will be positively received by the lymphoma treatment community on the basis of the PIX 301 clinical trial results and the lack of satisfactory alternative therapies for their patients with multiple relapsed aggressive non-Hodgkin's lymphoma."

What They Do: Cell Theraputics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.